Tetra Bio-Pharma closes $10M public offering to fund drug research
CEO Guy Chamberland told OBJ earlier this year firm is working on breakthrough treatments for sepsis and acute respiratory distress syndrome.
Tetra Bio-Pharma closes $10M public offering to fund drug research
CEO Guy Chamberland told OBJ earlier this year firm is working on breakthrough treatments for sepsis and acute respiratory distress syndrome.
Ottawa drug-maker Tetra Bio-Pharma’s decade-long research effort may be poised to pay off
Product is designed to treat life-threatening conditions triggered when the body’s immune system “goes rogue” in response to infections such as COVID-19.
Get up-to-date news about the companies, people and issues that impact businesses in Ottawa and beyond.
Sponsored
Didn’t we just do this? More changes coming to the Ontario Construction Act
Do I need an engineer for my construction project?
EVENT ALERT: Mayor's Breakfast with Ontario Finance Minister on Wednesday, Dec. 4 @ City Hall